Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)
Tweet Send to a Friend
Wells Fargo analyst Yanan Zhu reiterated an Overweight rating and $50.00 price target on Avidity Biosciences (NASDAQ: RNA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


